TOG Review (RCOG Journal)

MRCOG Part 2

Sexual and Reproductive Health

Female sexual dysfunction

Key Statistics

  • 30–60% — Prevalence of sexual problems in women
  • 21% — Women with problems who seek help
  • 98% — Sexual concerns in gynae clinic attenders

Don't-miss facts

  1. FSD criteria: present >75% of time, >6 months, causing significant distress

  2. DSM-5: desire+arousal merged → sexual desire/arousal disorder; dyspareunia+vaginismus merged → genito-pelvic pain/penetration disorder

  3. Only 21% of affected women seek help despite 30–60% prevalence – ask the screening question routinely

  4. Basson's circular model: orgasm not essential for fulfilment; intimacy/emotional connection drives the cycle

  5. Oophorectomy <50 years → consider HRT (± testosterone) for abrupt hormone loss

  6. Testosterone trial: 3–6 months, check level at baseline + 3–6 weeks, then 6-monthly if continued

  7. Failure to warn about post-surgical sexual dysfunction risk (e.g. vulvectomy, oophorectomy) is a recognised litigation risk

  8. No surgery is designed to treat FSD – discuss realistic sexual-function expectations before any gynae operation

Evidence at a glance

Supported: pelvic floor physio, vaginal dilators + topical estrogen, topical/vaginal estrogen, testosterone (low desire), ospemifene (SERM)

Not licensed/insufficient evidence: sildenafil (FSD), flibanserin (UK), genital cosmetic surgery, hypnosis/TENS-type modalities

Abbreviation Key

  • FSD — female sexual dysfunction
  • SUI — stress urinary incontinence
  • DSM — Diagnostic and Statistical Manual of Mental Disorders
  • POP — pelvic organ prolapse
  • ICD-10 — International Statistical Classification of Diseases and
  • RCT — randomised controlled trial Related Health Problems
  • HRT — hormone replacement therapy
  • ICSM — International Consultation of Sexual Medicine
  • FGM — female genital mutilation
  • IUGA — International Urogynecological Association
  • PTSD — post-traumatic stress disorder
  • ICS — International Continence Society
  • CBT — cognitive behavioural therapy
  • NATSAL — National Surveys of Sexual Attitudes and Lifestyles
  • IPM — Institute of Psychosexual Medicine
  • GP — general practitioner
  • SERM — selective estrogen receptor modulator (ospemifene)
  • LOFTI — listening, observing, feelings, thinking and interpreting
  • SSRI — selective serotonin reuptake inhibitor
  • FSFI — Female Sexual Function Index
  • cGMP — cyclic guanosine monophosphate
  • PISQ-31 / PISQ-IR — Prolapse and Incontinence Sexual Function
  • VIP — vasoactive intestinal peptide Questionnaire / IUGA-Revised
  • FDA — US Food and Drug Administration
  • GSM — genitourinary syndrome of menopause
  • NICE — National Institute for Health and Care Excellence
  • FSH — follicle-stimulating hormone
  • ACOG — American College of Obstetrics and Gynecology

Source: Kershaw V, Jha S. Female sexual dysfunction. The Obstetrician & Gynaecologist 2022;24:12–23. doi:10.1111/tog.12778

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free